



Clinuvel Pharmaceuticals Limited (ASX: CUV)

Clinuvel is an Australian biopharmaceutical company focused on developing its leading photoprotective drug afamelanotide, for a range of UV and light related skin disorders. Clinuvel is headquartered in Melbourne with one operational office in Zürich and another planned to open on the US East Coast.

Facts	ASX Listed	2001
	Shares on Issue	303,168,665
	Options (unlisted)	15,110,000
	Conditional performance rights	3,670,000
	Top 50 own	69.25%
	52 weeks price range	\$0.185 - \$0.4
	Employees	26
People	Brenda Shanahan	Chair
	Dr Philippe Wolgen	CEO, Director
	Dr Helmer P.K. Agersborg	Chief Scientific Officer, Director
	Stanley McLiesh	Non-Executive Director
	Dr Roger Aston	Non-Executive Director
	L. Jack Wood	Non-Executive Director
	Dr Dennis Wright	Manager, Clinical and Regulatory Affairs
Darren Keamy	CFO	
Head office contact	Phone	+61 3 9660 4900
	Fax	+61 3 9660 4999
	Email (general)	mail@clinuvel.com
	Email (investors)	investorrelations@clinuvel.com
	Postal address	Clinuvel Pharmaceuticals Ltd Level 11, 330 Collins St Melbourne, Vic 3000 Australia
European office contact	Phone	+41 44 253 75 00
	Fax:	+41 44 253 75 01
	Postal Address	Clinuvel AG Hauserstrasse 14 8032 Zürich Switzerland
Australian Share Registry	Name	Computershare
	Phone	+61 3 9415 4000
	Online	www.computershare.com.au
	Postal address	Yarra Falls, 452 Johnson St Abbotsford, Vic 3067 Australia
US ADR Registrar and Transfer Agent	Clinuvel ASX Symbol	CUV
	Name	Bank of New York Mellon
	Phone	+61 3 9640 3907
	Online	www.bankofny.com
	Postal Address	350 Collins St Melbourne, Vic 3000 Australia
German Xetra	Clinuvel ADR Symbol	CLVLY
	Clinuvel Xetra Symbol	UR 9
	For more information, log onto	http://bit.ly/9A5IKW

About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Ltd is a leading and innovative Australian company focused on the development of afamelanotide, its proprietary first-in-class photoprotective drug. Clinuvel has identified five groups of patients with a clinical need for photoprotection. Currently, Clinuvel is in its final stages to complete testing of afamelanotide in Phase II and III trials in Australia and Europe. Clinuvel's ongoing focus is to demonstrate the safety and efficacy of afamelanotide. Pending positive clinical results, Clinuvel aims to file afamelanotide for its first market approval for the orphan indications porphyria (EPP) and solar urticaria (SU).

About afamelanotide

Afamelanotide is a first-in-line therapeutic being developed by Clinuvel. An analogue of α -MSH, afamelanotide is a linear peptide which activates the skin to activate and produce eumelanin, the dark pigment which is known to have photoprotective properties (providing skin protection against light and UV radiation). Increased pigmentation of the skin appears a few days after administration of afamelanotide and lasts up to 60 days. Afamelanotide is administered underneath the skin as a dissolvable implant approximately the size of a grain of rice.

Clinuvel is currently testing afamelanotide in five clinical indications:

Indication	Description	Clinical Trial Status
Erythropoietic Protoporphyrria (EPP)	Absolute sun/UV intolerance	Phase III trial full results due Confirmatory Phase III trial approved August 2009
Solar Urticaria (SU)	Acute anaphylactic reaction to sun/UV	Phase II trial results reported July 2009
Photodynamic Therapy (PDT) - systemic	Phototoxicity following cancer treatment	Phase II trial results reported December 2009
Actinic Keratosis (AK) and Squamous Cell Carcinoma (SCC) in Organ Transplant Recipients (OTRs)	Skin cancer in transplant patients	Phase II trial started October 2007
Polymorphic Light Eruption (PLE / PMLE)	Severe sun/UV poisoning	Phase III trial preliminary results due

Phase I and II human clinical trials using afamelanotide have demonstrated that the drug is well tolerated and no significant safety concerns have been identified to date.

Following successful conclusion of the development program, Clinuvel will work closely with global regulators to facilitate marketing approval of afamelanotide.

For more information contact:

Lachlan Hay
Head of Global Network and Communications
Clinuvel Pharmaceuticals Limited
Tel: +61 3 9660 4900
investorrelations@clinuvel.com

Updated January 29, 2010

Clinuvel is an Australian biopharmaceutical company focused on developing its leading drug candidate, afamelanotide, for a range of UV-related skin disorders resulting from exposure of the skin to harmful UV radiation. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following:

- actual results may and often will differ materially from these forward-looking statements;
- no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for afamelanotide can or will be achieved;
- no assurances can be given by Clinuvel that, even if its development program for afamelanotide is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place.